Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2021-04-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司独立董事对公司对外担保情况的专项说明
Audit Report / Information Classification · 90% confidence The document is a special statement by independent directors regarding the company's external guarantees for the year 2020. It references regulatory notices from the China Securities Regulatory Commission about external guarantees and related party transactions. The content is a detailed explanation and confirmation of the external guarantee situation, including amounts, dates, and relationships, but it is not a full audit report or annual report. It is a specific disclosure related to external guarantees, which aligns with the nature of an Audit Report / Information filing rather than a full Annual Report or other categories. The document length is short (1548 characters), but it contains substantive information about the guarantees, not just an announcement or certification. Therefore, the best fit is Audit Report / Information (AR). FY 2020
2021-04-14 Chinese
江苏浩欧博生物医药股份有限公司2020年年度报告
Annual Report Classification · 100% confidence The document is titled "2020 年年度报告" which translates to "2020 Annual Report". It is issued by 江苏浩欧博生物医药股份有限公司 (Jiangsu HOB Biotech Group Corp., Ltd.). The text includes detailed financial data, company business overview, risk disclosures, profit distribution plans, governance information, and extensive financial tables. It also mentions an audit report with an unqualified opinion by an accounting firm, which is typical for an annual report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The content covers comprehensive financial performance and business operations for the full fiscal year 2020. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-14 Chinese
江苏浩欧博生物医药股份有限公司关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy related to the adoption of a new lease accounting standard. It includes details about the reason for the change, the approval process by the board and supervisory committee, and opinions from independent directors and the supervisory board. The document does not contain full financial statements or comprehensive financial data but rather informs about the policy change and its expected impact. The document length is short (1439 characters), and it serves as a formal announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-14 Chinese
江苏浩欧博生物医药股份有限公司第二届董事会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It includes approvals of the 2020 annual report, financial statements, work reports, profit distribution plan, internal control evaluation report, and other governance matters. The document repeatedly states that these reports and plans will be submitted to the 2020 annual shareholders' meeting for approval and are available on the Shanghai Stock Exchange website. The document itself does not contain the full annual report or financial statements but is a formal announcement of board meeting decisions related to the annual report and other governance issues. The document length is 3713 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of board resolutions and report approvals, not the full annual report itself.
2021-04-14 Chinese
江苏浩欧博生物医药股份有限公司2020年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2020 年度内部控制评价报告' which translates to '2020 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2020, including financial and non-financial internal control defects, their identification, and remediation status. The document is a detailed report on internal control evaluation, which is typically part of audit-related disclosures but is not a full annual report or audit opinion by an external auditor. It does not contain full financial statements or comprehensive financial performance data. The document length is 4149 characters, which is relatively short but contains substantive content on internal control evaluation. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2020
2021-04-14 Chinese
江苏浩欧博生物医药股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint an accounting firm (Lixin CPA Firm) as the auditor for the 2021 fiscal year. It details the qualifications of the accounting firm, the audit committee's review, independent directors' opinions, and board and supervisory committee approvals. There is no actual audit report or financial statements included, nor is there detailed financial data or analysis. The document is relatively short (3986 characters) and serves as a formal announcement of the auditor appointment rather than the audit report itself. Therefore, it fits best into the category of Audit Report / Information (AR), which includes standalone audit reports and related information such as auditor appointments and audit firm details, but excludes full annual reports. The document is not a full annual report (10-K), nor a report publication announcement (RPA), nor a regulatory filing (RNS) since it is a substantive announcement about audit firm reappointment. FY 2021
2021-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.